title: Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone.
abstract: OBJECTIVE
  To determine the efficacy of, and compliance with, glimepiride or acarbose in patients with Type 2 diabetes.
  
  
  METHODS
  Two hundred and nineteen patients with Type 2 diabetes uncontrolled by diet alone were randomized to receive either glimepiride (1, 2, 3, 4 or 6 mg once daily, n = 111) or acarbose (50, 100, 150 or 200 mg 3 times daily, n = 108). Both drugs were titrated in a 6-week dose-finding phase to achieve a fasting blood glucose (FBG) concentration < or = 7.8 mmol/ (140 mg/dl). Patients achieving this target entered a 20-week treatment period. Efficacy was assessed by responder rate, number of patients achieving a FBG of < or = 7.8 mmol/l, HbA1c, blood glucose concentrations in response to a standard breakfast, body weight and compliance.
  
  
  RESULTS
  Glimepiride was associated with a significantly greater responder rate than acarbose (61 vs 34%, p < 0.001), significantly greater decreases in HbA1c (2.5 +/- 2.2% vs 1.8 +/- 2.2%, p = 0.014) and FBG (2.6 +/- 2.6 mmol/l vs 1.4 +/- 2.8 mmo/l, p = 0.004), a decreased glucose response to breakfast compared with acarbose [area under curve (AUC) end: 8.9 +/- 2.7 mmol/l vs 11.3 +/- 3.9 mmol/l, p = 0.0001], and was accompanied by significantly greater compliance (91 < or = 12% vs 66 +/- 26%, p = 0.0001). Weight loss during the study was observed in both the acarbose group (1.9 +/- 3.9 kg, p = 0.001) and glimepiride group [0.4 +/- 5.2 kg, p = 0.8 (NS)].
  
  
  CONCLUSIONS
  Improved efficacy and greater compliance were observed in response to treatment with glimepiride compared with acarbose, in patients with Type 2 diabetes.
authors.affiliation: 3rd Department of Internal Medicine, City Hospital Lainz, Vienna, Austria. fec@3me.khl.magwien.gv.at
authors.forename: C
authors.initials: C
authors.lastname: Feinböck
authors.forename: A
authors.initials: A
authors.lastname: Luger
authors.forename: A
authors.initials: A
authors.lastname: Klingler
authors.forename: T
authors.initials: T
authors.lastname: Egger
authors.forename: G Kacerovsky
authors.initials: GK
authors.lastname: Bielesz
authors.forename: F
authors.initials: F
authors.lastname: Winkler
authors.forename: A
authors.initials: A
authors.lastname: Siebenhofer
authors.forename: F
authors.initials: F
authors.lastname: Grossschädl
authors.forename: E
authors.initials: E
authors.lastname: Frank
authors.forename: K
authors.initials: K
authors.lastname: Irsigler
mesh_terms: D020909:Acarbose / Q000627:therapeutic use*; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000178:diet therapy / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
chemical_list: D020909:Acarbose; D001786:Blood Glucose; D002096:C-Peptide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride